Lipocine (NASDAQ:LPCN) Rating Lowered to “Sell” at Wall Street Zen

Lipocine (NASDAQ:LPCN) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

LPCN has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective (up from $7.00) on shares of Lipocine in a report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Lipocine has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Lipocine Stock Performance

Shares of NASDAQ:LPCN opened at $7.34 on Friday. The company’s fifty day moving average is $9.08 and its 200-day moving average is $5.37. Lipocine has a 52 week low of $2.52 and a 52 week high of $12.37. The company has a market capitalization of $53.58 million, a PE ratio of -4.35 and a beta of 0.98.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Monday, March 9th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%. The business had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.12 million.

Institutional Investors Weigh In On Lipocine

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LPCN. Renaissance Technologies LLC raised its stake in shares of Lipocine by 3.6% in the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after acquiring an additional 1,300 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Lipocine by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after purchasing an additional 1,374 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Lipocine in the fourth quarter valued at approximately $85,000. Citadel Advisors LLC bought a new position in Lipocine in the 3rd quarter worth approximately $41,000. Finally, Boothbay Fund Management LLC bought a new position in Lipocine in the 4th quarter worth approximately $441,000. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.